Clinical trial
Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)
NCT03099031 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)
- Lead sponsor
- LEO Pharma
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2015
- Completion date
- May 15, 2017
- Enrollment
- 420 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.